Quick Answer
Matinas BioPharma Holdings, Inc. reported Cash And Cash Equivalents At Carrying Value of $4.00 million for the year ending 2025.
- Matinas BioPharma Holdings, Inc. showed a decrease of -45.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Matinas BioPharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $461.5 thousand | Q3 2013: $12.57 million | Q1 2014: $8.56 million | Q2 2014: $6.65 million | Q3 2014: $5.01 million | Q1 2015: $4.62 million | Q2 2015: $6.61 million | Q3 2015: $4.36 million | Q1 2016: $1.67 million | Q2 2016: $578.3 thousand | Q3 2016: $6.22 million | Q4 2016: $4.11 million | Q1 2017: $15.83 million | Q2 2017: $11.27 million | Q3 2017: $9.00 million | Q4 2017: $7.31 million | Q1 2018: $4.26 million | Q2 2018: $8.90 million | Q3 2018: $6.63 million | Q1 2019: $39.41 million | Q2 2019: $36.83 million | Q3 2019: $32.66 million | Q1 2020: $10.08 million | Q2 2020: $14.90 million | Q3 2020: $7.05 million | Q1 2021: $23.38 million | Q2 2021: $30.35 million | Q3 2021: $24.92 million | Q1 2022: $19.33 million | Q2 2022: $10.40 million | Q3 2022: $11.18 million | Q1 2023: $5.74 million | Q2 2023: $9.74 million | Q3 2023: $6.41 million | Q1 2024: $1.07 million | Q2 2024: $4.22 million | Q3 2024: $10.30 million | Q1 2025: $6.92 million | Q2 2025: $6.53 million | Q3 2025: $5.44 million.
- Over the full 14 years of available data (2012 to 2025), Matinas BioPharma Holdings, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 842.4%.
- Historical annual values: Fiscal year 2025: $4.00 million | Fiscal year 2024: $7.28 million | Fiscal year 2023: $4.79 million | Fiscal year 2022: $6.83 million | Fiscal year 2021: $21.03 million | Fiscal year 2020: $12.43 million | Fiscal year 2019: $22.17 million | Fiscal year 2018: $12.45 million | Fiscal year 2017: $7.31 million | Fiscal year 2016: $4.11 million | Fiscal year 2015: $3.23 million | Fiscal year 2014: $2.59 million | Fiscal year 2013: $10.84 million | Fiscal year 2012: $424.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: